Work

Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response

Year: 2007
Type: review
Abstract: Tamoxifen continues to be a standard endocrine therapy for the prevention and treatment of estrogen receptor (ER)-positive breast cancer. Tamoxifen can be considered a classic "pro-drug," requiring metabolic activation to elicit pharmacological activity. CYP2D6 is the rate-limiting enzyme catalyzing the conversion of tamoxifen into metabolites with significantly greater affinity for the ER and greater ability to inhibit cell proliferation. Both genetic and environmental (drug-induced) factors that alter CYP2D6 enzyme activity directly affect the concentrations of the active tamoxifen metabolites and the outcomes of patients receiving adjuvant tamoxifen. The a priori knowledge of the pharmacogenetic variation known to abrogate CYP2D6 enzyme activity may provide a means by which the hormonal therapy of breast cancer can be individualized.
Institution: Mayo Clinic
Language: English
Subfield: Pharmacology
Open Access status: green
OpenAlex ID: W2164681558
FWCI: 2.88
Cites: 56
Cited by: 220
Related to: 9